The purpose of this study, in de novo heart transplant patients, is to evaluate whether
delayed introduction of everolimus reduces the occurrence of wound healing problems,
pericardial and/or pleural effusion and early acute renal insufficiency, as compared with
immediate introduction of everolimus, in the firs six months after heart transplantation.